echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > CFDA approves Gilead propien sand ® for treatment of adult strains with chronic hepatitis C virus 1-6

    CFDA approves Gilead propien sand ® for treatment of adult strains with chronic hepatitis C virus 1-6

    • Last Update: 2020-06-11
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Gilead ScientificCompany(NASDAQ: GILD) announced that the NationalDrug(the Supervisory Authority approved the propane sand ® (Sophobuvir 400 mg / Vipatavir 100 mg) can be used to treat adult strains of chronic hepatitis C virus (HCV) with the gene 1-6the State Drug Administration also approved the use of cat-sand ® combined ribavirin (RBV) for adult patients with hepatitis C during the combined replacement period of cirrhosisprotosconosis ® is the first ugenous HCV single tablet program (STR) approved in Chinaclenbutechon sand ® is approved in China, based on five international multicenter Phase 3 clinical studies, namely ASTRAL-1, ASTRAL-2, ASTRAL-3, ASTRAL-4 and ASTRAL-5In a hard-to-cure group of patients (including treated patients, as well as patients with trified or indemnity cirrhosis), SVR12 (defined as the 12th week after completion of treatment) had a higher overall achievement rate of 92%-100% of thedetection(not HCV RNA)in the ASTRAL-1, ASTRAL-2, and ASTRAL-3 studies, 1,035 first-treatment and treated patients with type 1-6 HCV infection without cirrhosis/associated period of cirrhosis received 12 weeks of propane ® treatment98% (1,015/1,035) of patients achieved SVR12In the ASTRAL-5 study, 106 first-treatment and treatable patients with type 1-6 HCV infection with non-cured cirrhosis/associated cirrhosis received 12 weeks of propane ® treatment, as well as HIV infection and were receiving stable antiretroviral treatmentOf these, 95% (101/106) of patients achieved SVR12The ASTRAL-4 study assessed the safety and efficacy of 267 patients with gene 1-4 and Genotype 6 HCV infections who received 12-week propane-®/non-joint ribavirin (RBV) treatment or 24-week propane ® therapyOf these, 94% (82/87) of SVR12 was achieved in patients with out-of-paid cirrhosis treated with 12 weeks of propane ® combined with RBV adverse reactions
    the most common adverse reactions (-10%) of patients treated with propane-sand ® in ASTRAL-1, ASTRAL-2, and ASTRAL-5 include headaches and fatigue In the ASTRAL-1 study, patients in the placebo group experienced similar frequency of headaches and fatigue In ASTRAL-4, the most common adverse reactions after treatment with propane salin ® and ribavirin (RBV) included fatigue, anemia, nausea, headache, insomnia, and diarrhea in patients with renuncitruary cirrhosis Four patients taking cactus ® combined WITH RBV were discontinued due to adverse reactions
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.